EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review

Feng Ji iD, Lijuan Ma, Xuning Shen, Xiaoling Liang, Wei Cui, Yucong Zhou, Xi-En Wang, Hao Liu iD

Therapeutic Advances in Psychopharmacology · 2026-08 · 16

DOI: 10.1177/20451253261478086 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 18.08.2026. Verfasst von Feng Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Affiliated People's Hospital of Ningbo University, Zhejiang, China. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation, Ningbo Public Welfare Research Program, Ningbo Yongjiang Talent Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This narrative review summarizes the latest clinical evidence on xanomeline-trospium in schizophrenia, a first-in-class centrally acting dual-target muscarinic receptor modulator. Xanomeline-trospium combines the muscarinic receptor agonist xanomeline, with with functional preference for M1/M4 subtypes, and the peripherally acting muscarinic antagonist trospium chloride in a 4.2:1 ratio. Xanomeline mediates central therapeutic effects, whereas trospium mitigates xanomeline-induced peripheral adverse effects, including nausea, vomiting, and diarrhea. Five EMERGENT trials were reviewed, comprising three short-term efficacy studies and two long-term extension studies evaluating efficacy and safety. In five-week short-term trials, xanomeline-trospium significantly reduced total Positive and Negative Syndrome Scale (PANSS) total scores, with reductions in positive symptoms approximately 1.5-2 times greater and negative symptoms 1.5-3.5 times greater than those observed with placebo. In the EMERGENT-4 and EMERGENT-5 long-term extension trials, sustained therapeutic effects were observed along with potential improvements in quality of life in patients with mild-to-moderate schizophrenia over 52 weeks. Nevertheless, tolerability remains a major challenge, with high overall discontinuation rates (EMERGENT-4: 78.2% discontinuation; EMERGENT-5: 51% withdrawal). Notably, voluntary withdrawal accounted for a substantial proportion of discontinuations, exceeding adverse event-related withdrawals in certain subgroups. The most common adverse events included gastrointestinal symptoms (nausea, constipation, vomiting) and syncope. Compared with traditional dopamine D2 antagonists, xanomeline-trospium was associated with lower risks of weight gain, hyperprolactinemia, and extrapyramidal symptoms. Key limitations of this review include reliance on placebo-controlled trials without head-to-head comparisons, exclusion of treatment-resistant schizophrenia populations, and limited generalizability to outpatient settings due to the focus on acute inpatient cohorts. Future research should focus on identifying risk factors for early discontinuation and developing both pharmacological and non-pharmacological strategies to improve long-term adherence. Overall, as a novel non-dopaminergic antipsychotic strategy, xanomeline-trospium offers an important therapeutic option for patients who are intolerant to the metabolic or motor adverse effects of traditional antipsychotics, although challenges related to long-term adherence remain to be addressed.

Schlagwörter

Stichwörter der Autor:innen

drug safetymuscarinic acetylcholine receptorsnarrative reviewschizophreniaxanomeline-trospium

Autor:innen und Institutionen

  • Department of Internal Medicine, The Affiliated People's Hospital of Ningbo University, Zhejiang, China.
  • College of Biological and Environmental Science, Zhejiang Wanli University, Ningbo, P. R. China.

ORCID-Profile: Feng Ji, Hao Liu

Förderung

  • Zhejiang Provincial Natural Science Foundation
  • Ningbo Public Welfare Research Program
  • Ningbo Yongjiang Talent Programme
  • Marine Industry Science and TechnologyProject of Zhejiang Province
  • Ningbo Medical & Health LeadingAcademic Discipline Project

Zitieren

APA

Ji, F., Ma, L., Shen, X., Liang, X., Cui, W., Zhou, Y., Wang, X. E., & Liu, H. (2026). The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261478086

Vancouver

Ji F, Ma L, Shen X, Liang X, Cui W, Zhou Y, et al. The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261478086

BibTeX
@article{Ji2026,
  author = {Ji, Feng and Ma, Lijuan and Shen, Xuning and Liang, Xiaoling and Cui, Wei and Zhou, Yucong and Wang, Xi-En and Liu, Hao},
  title = {The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253261478086}
}
Kostenlos starten →